share_log

Alnylam Pharmaceuticals Shares Are Trading Higher After the Company Secured FDA Approval Pf SNDA for Its RNAi Therapeutic, AMVUTTRA ,for Treatment of ATTR-CM in Adults.

Alnylam Pharmaceuticals Shares Are Trading Higher After the Company Secured FDA Approval Pf SNDA for Its RNAi Therapeutic, AMVUTTRA ,for Treatment of ATTR-CM in Adults.

阿里拉姆制藥的股票在公司獲得FDA對其RNAi治療藥物AMVUTTRA用於治療成人ATTR-CM的SNDA批准後上漲。
Benzinga ·  03/21 12:11

Alnylam Pharmaceuticals Shares Are Trading Higher After the Company Secured FDA Approval Pf SNDA for Its RNAi Therapeutic, AMVUTTRA ,for Treatment of ATTR-CM in Adults.

阿里拉姆制藥的股票在公司獲得FDA對其RNAi治療藥物AMVUTTRA用於治療成人ATTR-CM的SNDA批准後上漲。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 1022

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。